Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)

Christine Tagliaferri Rael; Javier Lopez-Ríos; Stacey A. McKenna; Doyel Das; Curtis Dolezal; Elena Abascal; Alex Carballo-Diéguez; Rebecca Schnall; Thomas J. Hope; José Bauermeister; Walter Bockting

doi:10.1007/s10461-021-03357-y

Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)

Christine Tagliaferri Rael^*, Javier Lopez-Ríos, Stacey A. McKenna, Doyel Das, Curtis Dolezal, Elena Abascal, Alex Carballo-Diéguez, Rebecca Schnall, Thomas J. Hope, José Bauermeister, Walter Bockting

^*Corresponding author for this work

Cell & Developmental Biology

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Long-acting injectable cabotegravir (CAB-LA) is in advanced stages of clinical trials. Under the standard protocol, CAB-LA is injected into the gluteal muscle by a healthcare provider every eight weeks. To explore transgender women’s barriers and facilitators to tailored delivery strategies—including self-injection and injection in “drop-in” centers—we completed in-depth interviews with N = 15 transgender women in New York City. Participants endorsed the alternative delivery methods and the corresponding features we proposed, and expressed likes and dislikes about each. These fell into the following categories: competence (e.g., the person delivering CAB-LA must have skills to do so), convenience (e.g., CAB-LA must be easy to obtain), and privacy or fear of judgement (e.g., participants did not want to feel judged for using CAB-LA by providers or other service consumers). Findings suggest the need to offer CAB-LA to transgender women through multiple delivery protocols.

Original language	English (US)
Pages (from-to)	4180-4192
Number of pages	13
Journal	AIDS and behavior
Volume	25
Issue number	12
DOIs	https://doi.org/10.1007/s10461-021-03357-y
State	Published - Dec 2021

Funding

The first author is supported by a K01 Award (K01 MH115785; Principal Investigator: Christine Tagliaferri Rael, Ph.D.) from the National Institute of Mental Health at the HIV Center for Clinical and Behavioral Studies at the NY State Psychiatric Institute (NYSPI) and Columbia University (P30 MH43520; Center Principal Investigator: Robert Remien, Ph.D.), and the Program for the Study of LGBT Health at NYSPI/Columbia University and with the Columbia University School of Nursing. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health.

Keywords

Injectable cabotegravir
Long-acting cabotegravir
PrEP
Transgender women

ASJC Scopus subject areas

Public Health, Environmental and Occupational Health
Infectious Diseases
Social Psychology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10461-021-03357-y

Cite this

Rael, C. T., Lopez-Ríos, J., McKenna, S. A., Das, D., Dolezal, C., Abascal, E., Carballo-Diéguez, A., Schnall, R., Hope, T. J., Bauermeister, J., & Bockting, W. (2021). Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP). AIDS and behavior, 25(12), 4180-4192. https://doi.org/10.1007/s10461-021-03357-y

@article{baa060ea85db4c239bb49df0a8b4c9df,

title = "Transgender Women{\textquoteright}s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)",

abstract = "Long-acting injectable cabotegravir (CAB-LA) is in advanced stages of clinical trials. Under the standard protocol, CAB-LA is injected into the gluteal muscle by a healthcare provider every eight weeks. To explore transgender women{\textquoteright}s barriers and facilitators to tailored delivery strategies—including self-injection and injection in “drop-in” centers—we completed in-depth interviews with N = 15 transgender women in New York City. Participants endorsed the alternative delivery methods and the corresponding features we proposed, and expressed likes and dislikes about each. These fell into the following categories: competence (e.g., the person delivering CAB-LA must have skills to do so), convenience (e.g., CAB-LA must be easy to obtain), and privacy or fear of judgement (e.g., participants did not want to feel judged for using CAB-LA by providers or other service consumers). Findings suggest the need to offer CAB-LA to transgender women through multiple delivery protocols.",

keywords = "Injectable cabotegravir, Long-acting cabotegravir, PrEP, Transgender women",

author = "Rael, {Christine Tagliaferri} and Javier Lopez-R{\'i}os and McKenna, {Stacey A.} and Doyel Das and Curtis Dolezal and Elena Abascal and Alex Carballo-Di{\'e}guez and Rebecca Schnall and Hope, {Thomas J.} and Jos{\'e} Bauermeister and Walter Bockting",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

month = dec,

doi = "10.1007/s10461-021-03357-y",

language = "English (US)",

volume = "25",

pages = "4180--4192",

journal = "AIDS and behavior",

issn = "1090-7165",

publisher = "Springer New York",

number = "12",

}

Rael, CT, Lopez-Ríos, J, McKenna, SA, Das, D, Dolezal, C, Abascal, E, Carballo-Diéguez, A, Schnall, R, Hope, TJ, Bauermeister, J & Bockting, W 2021, 'Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)', AIDS and behavior, vol. 25, no. 12, pp. 4180-4192. https://doi.org/10.1007/s10461-021-03357-y

Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP). / Rael, Christine Tagliaferri; Lopez-Ríos, Javier; McKenna, Stacey A. et al.
In: AIDS and behavior, Vol. 25, No. 12, 12.2021, p. 4180-4192.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)

AU - Rael, Christine Tagliaferri

AU - Lopez-Ríos, Javier

AU - McKenna, Stacey A.

AU - Das, Doyel

AU - Dolezal, Curtis

AU - Abascal, Elena

AU - Carballo-Diéguez, Alex

AU - Schnall, Rebecca

AU - Hope, Thomas J.

AU - Bauermeister, José

AU - Bockting, Walter

PY - 2021/12

Y1 - 2021/12

N2 - Long-acting injectable cabotegravir (CAB-LA) is in advanced stages of clinical trials. Under the standard protocol, CAB-LA is injected into the gluteal muscle by a healthcare provider every eight weeks. To explore transgender women’s barriers and facilitators to tailored delivery strategies—including self-injection and injection in “drop-in” centers—we completed in-depth interviews with N = 15 transgender women in New York City. Participants endorsed the alternative delivery methods and the corresponding features we proposed, and expressed likes and dislikes about each. These fell into the following categories: competence (e.g., the person delivering CAB-LA must have skills to do so), convenience (e.g., CAB-LA must be easy to obtain), and privacy or fear of judgement (e.g., participants did not want to feel judged for using CAB-LA by providers or other service consumers). Findings suggest the need to offer CAB-LA to transgender women through multiple delivery protocols.

AB - Long-acting injectable cabotegravir (CAB-LA) is in advanced stages of clinical trials. Under the standard protocol, CAB-LA is injected into the gluteal muscle by a healthcare provider every eight weeks. To explore transgender women’s barriers and facilitators to tailored delivery strategies—including self-injection and injection in “drop-in” centers—we completed in-depth interviews with N = 15 transgender women in New York City. Participants endorsed the alternative delivery methods and the corresponding features we proposed, and expressed likes and dislikes about each. These fell into the following categories: competence (e.g., the person delivering CAB-LA must have skills to do so), convenience (e.g., CAB-LA must be easy to obtain), and privacy or fear of judgement (e.g., participants did not want to feel judged for using CAB-LA by providers or other service consumers). Findings suggest the need to offer CAB-LA to transgender women through multiple delivery protocols.

KW - Injectable cabotegravir

KW - Long-acting cabotegravir

KW - PrEP

KW - Transgender women

UR - http://www.scopus.com/inward/record.url?scp=85109284860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109284860&partnerID=8YFLogxK

U2 - 10.1007/s10461-021-03357-y

DO - 10.1007/s10461-021-03357-y

M3 - Article

C2 - 34216284

AN - SCOPUS:85109284860

SN - 1090-7165

VL - 25

SP - 4180

EP - 4192

JO - AIDS and behavior

JF - AIDS and behavior

IS - 12

ER -

Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this